- Composition of matter patent issued with coverage until June 2043
- Patent also includes methods of use and methods of manufacturing claims
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,926,669 ("the ‘669 patent") for IMVT-1402, the Company's second-generation antibody targeting the neonatal fragment crystallizable receptor (FcRn). The allowed claims cover composition of matter for the binding sequence of IMVT-1402 to FcRn, method of use of the antibody for treating autoimmune disease, as well as methods for its manufacturing. Not including any potential patent term extension, the ‘669 patent will expire on June 23, 2043. IMVT-1402 is being developed by Immunovant based on antibody discovery efforts by HanAll Biopharma.
IMVT-1402 delivered subcutaneously has demonstrated potentially best-in-class profile in a Phase 1 clinical trial in healthy adults, with initial data demonstrating a deep immunoglobulin G (IgG) reduction that is similar to batoclimab, but with no or minimal changes in serum albumin and LDL cholesterol, consistent with placebo. Immunovant believes that IMVT-1402 administered weekly can achieve steady reductions in IgG and further believes that steady reductions in IgG lowering are needed to avoid fluctuations in efficacy.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology ...